WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 610232
CAS#: 877397-65-4
Description: Crizotinib Interm 7654 is an important intermediate for the synthesis of pharmaceutical compounds.
MedKoo Cat#: 610232
Name: Crizotinib Interm 7654
CAS#: 877397-65-4
Chemical Formula: C8H7Cl2FO
Exact Mass: 207.9858
Molecular Weight: 209.04
Elemental Analysis: C, 45.96; H, 3.38; Cl, 33.92; F, 9.09; O, 7.65
Synonym: Crizotinib Interm 7654; Crizotinib Intermediate; (S)-1-(2,6-Dichloro-3- fluorophenyl)ethanol; BenzeneMethanol,2,6-dichloro-3-fluoro-a-Methyl-, (aS)-;(1S)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol;(S)-1-(2,6 -dichloro-4-fluorophenyl)ethanol
IUPAC/Chemical Name: (1S)-1-(2,6-dichloro-3-fluorophenyl)ethanol
InChi Key: JAOYKRSASYNDGH-UHFFFAOYSA-N
InChi Code: InChI=1S/C8H7Cl2FO/c1-4(12)7-5(9)2-3-6(11)8(7)10/h2-4,12H,1H3
SMILES Code: CC(C1=C(C=CC(=C1Cl)F)Cl)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 209.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10. PubMed PMID: 25517749; PubMed Central PMCID: PMC4269829.
2: Clegg IM, Daly AM, Donnelly C, Hardy R, Harris D, Jackman H, Jones R, Luan A, McAndrew D, McGauley P, Pearce J, Scotney G, Yeow ML. Application of mid-infrared spectroscopy to the development and transfer of a manufacturing process for an active pharmaceutical ingredient. Appl Spectrosc. 2012 May;66(5):574-9. doi: 10.1366/11-06380. PubMed PMID: 22524963.
3: Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18. PubMed PMID: 21502504; PubMed Central PMCID: PMC3088626.
